HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY
Clinical trials for HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY trials appear
Sign up with your email to follow new studies for HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental triple therapy takes on head and neck cancer
Disease control OngoingThis early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…
Matched conditions: HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New proton beam therapy aims to zap head and neck cancer with fewer side effects
Disease control OngoingThis study is testing whether a precise form of radiation called proton therapy can control head and neck cancer after surgery as well as standard X-ray radiation, but with fewer side effects. About 174 adults with newly diagnosed head and neck cancer will receive either proton t…
Matched conditions: HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo therapy offers hope for head and neck cancer patients unable to take standard chemo
Symptom relief OngoingThis early-phase study tests the safety of combining the drug tolinapant with radiation therapy for people with head and neck cancer that has spread locally but hasn't been treated yet. Participants are those who cannot receive the standard chemotherapy drug cisplatin. The goal i…
Matched conditions: HEAD AND NECK CARCINOMA OF UNKNOWN PRIMARY
Phase: EARLY_PHASE1 • Sponsor: Emory University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC